Expressions of survivin and minichromosome maintenance protein 2 in breast carcinoma and their clinical significance

doi:10.3877/cma. j. issn.1674-0807.2013.04.004

Abstract

Abstract:

Objective

To study the expressions of survivin and minichromosome maintenance protein 2(MCM2) in breast cancer tissue, and explore their clinical significance in the development of breast cancer.

Methods

The expressions of survivin and MCM2 were detected using immunohistochemical staining SP method in 60 cases of breast cancer (the pathologic type was infiltrating ductal carcinoma) and 40 cases of breast fibroadenoma treated in Affiliated Hospital of Inner Mongolia Medical College from January 2003 to January 2007. χ² test and Spearman rank correlation analysis were used for data analysis.

Results

The positive expression rate of survivin in breast cancer tissue was significantly higher than that in the fibroadenoma(12.50%vs 71.67%;χ²=33.661,P=0.000). The survivin expression showed a significant correlation with the different histological grade of breast cancer (10.00%vs 58.33%;χ² =9.941, P=0.007). The positive expression rate of MCM2 in breast cancer tissue was significantly higher than that in the fibroadenoma (χ² =23.567, P = 0.000). The expression of MCM2 showed a significant correlation with tumor diameter,histological grade, clinical stage, axillary lymph node metastasis (χ²=4.239,9.307,5.126,6.655;P＜0.05).The expressions of survivin and MCM2 in breast cancer were positively correlated(r=0.294,P=0.023).

Conclusion

The expressions of survivin and MCM2 might be related to the development of breast cancer,which might be helpful in the diagnosis and prognosis of breast cancer.

Key words: Breast neoplasms, Immunohistochemistry, Survivin, Minichromosome maintenance protein 2

Dong-hai LI, Ming LIU. Expressions of survivin and minichromosome maintenance protein 2 in breast carcinoma and their clinical significance[J]. Chinese Journal of Breast Disease(Electronic Edition), 2013, 07(04): 254-258.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhrxbzz.cma-cmc.com.cn/EN/10.3877/cma. j. issn.1674-0807.2013.04.004

https://zhrxbzz.cma-cmc.com.cn/EN/Y2013/V07/I04/254

Figures/Tables 8

References 15

[1]	Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010[J].CA Cancer J Clin,2010,60(5):277-300.
[2]	Kelly RJ,Lopez-Chavez A,Citrin D,et al. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin[J]. Mol Cancer,2011,10:35.
[3]	Liu BB, Wang WH. Survivin and pancreatic cancer [J].World J Clin Oncol,2011,2(3):164-168.
[4]	Dudderidge TJ, Stoeber K, Loddo M, et al. Mcm2, Geminin,and KI67 define proliferative state and are prognostic markers in renal cell carcinoma [J]. Clin Cancer Res, 2005,11(7):2510-2517.
[5]	Gonzalez MA, Pinder SE, Callagy G, et al. Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer [J]. J Clin Oncol,2003,21(23):4306-4313.
[6]	Tachibana KE, Gonzalez MA, Coleman N. Cell-cycledependent regulation of DNA replication and its relevance to cancer pathology[J]. J Pathol,2005,205(2):123-129.
[7]	许良中,杨文涛. 免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231.
[8]	Adamkov M,Halasova E,Kajo K,et al. Survivin:a promising biomarker in breast carcinoma[J]. Neoplasma,2010,57(6):572-577.
[9]	Athanassiadou AM, Patsouris E, Tsipis A, et al. The significance of Survivin and Nectin-4 expression in the prognosis of breast carcinoma[J]. Folia Histochem Cytobiol,2011,49(1):26-33.
[10]	Spaulding B, Pan D, Ghadersohi A, et al. Characterization of the 12C4 survivin monoclonal antibody and insight into the expression of survivin in human adult tissues [ J ].Histopathology,2006,49(6):622-633.
[11]	Li F, Ling X. Survivin study: an update of “what is the next wave” ? [J]. J Cell Physiol,2006,208(3):476-486.
[12]	Jha K, Shukla M, Pandey M. Survivin expression and targeting in breast cancer[J].Surg Oncol,2012,21(2):125-131.
[13]	伦增军,黄勇,王静,等. 乳腺癌组织中survivin 和增殖细胞核抗原的表达及其临床意义[J/CD]. 中华乳腺病杂志:电子版,2009,3(3):301-308.
[14]	Tokuyasu N, Shomori K, Nishihara K, et al. Minichromosome maintenance 2 (MCM2) immunoreactivity in stage Ⅲhuman gastric carcinoma: clinicopathological significance[J]. Gastric Cancer,2008,11(1):37-46.
[15]	Shetty A, Loddo M, Fanshawe T, et al. DNA replication licensing and cell cycle kinetics of normal and neoplastic breast[J]. Br J Cancer,2005,93(11):1295-1300.

组别	例数	survivin 表达		阳性率(%)	χ ²值	P值
组别	例数	阴性	阳性	阳性率(%)	χ ²值	P值
乳腺纤维腺瘤	40	35	5	12.50	33.661	0.000
乳腺癌	60	17	43	71.67	33.661	0.000

组别	例数	survivin 表达		阳性率(%)	χ ²值	P值
组别	例数	阴性	阳性	阳性率(%)	χ ²值	P值
乳腺纤维腺瘤	40	35	5	12.50	33.661	0.000
乳腺癌	60	17	43	71.67	33.661	0.000

组别	例数	MCM2 蛋白表达		阳性率(%)	χ ²值	P值
组别	例数	阴性	阳性	阳性率(%)	χ ²值	P值
乳腺纤维腺瘤	40	36	4	10.00	23.567	0.000
乳腺癌	60	25	35	58.33	23.567	0.000

组别	例数	MCM2 蛋白表达		阳性率(%)	χ ²值	P值
组别	例数	阴性	阳性	阳性率(%)	χ ²值	P值
乳腺纤维腺瘤	40	36	4	10.00	23.567	0.000
乳腺癌	60	25	35	58.33	23.567	0.000

临床病理特征	例数	survivin表达(例)		χ ²值	P值	MCM2表达(例)		χ ²值	P值
临床病理特征	例数	+	-	χ ²值	P值	+	-	χ ²值	P值
年龄
≤50 岁	26	21	5	1.872	0.171	14	12	0.380	0.538
＞50 岁	34	22	12			21	13
肿瘤直径
≤2 cm	39	25	14	3.140	0.076	19	20	4.239	0.040
＞2 cm	21	18	3			16	5
组织学分级
Ⅰ	15	6	9	9.941	0.007	5	10	9.307	0.010
Ⅱ	26	21	5			14	12
Ⅲ	19	16	3			16	3
临床分期
Ⅰ～Ⅱ	38	25	13	1.763	0.184	18	20	5.126	0.024
Ⅲ	22	18	4			17	5
腋窝淋巴结转移
有	46	34	12	0.131	0.718	31	15	6.655	0.010
无	14	9	5			4	10

Please choose a citation manager

Content to export